Understanding Corcept Therapeutics – A Fundamental Overview

By Chris Stiles • Friday, April 18 15:09 • Permanent Link

One of the losers of today's trading session was Corcept Therapeutics. Shares of the Pharmaceutical company plunged -3.7%, and some investors may be wondering if its price of $62.24 would make a good entry point. Here's what you should know if you are considering this investment:

Corcept Therapeutics has moved 171.2% over the last year, and the S&P 500 logged a change of 6.4%
CORT has an average analyst rating of buy and is -56.55% away from its mean target price of $143.25 per share
Its trailing earnings per share (EPS) is $1.23
Corcept Therapeutics has a trailing 12 month Price to Earnings (P/E) ratio of 50.6 while the S&P 500 average is 29.3
Its forward earnings per share (EPS) is $1.75 and its forward P/E ratio is 35.6
The company has a Price to Book (P/B) ratio of 9.63 in contrast to the S&P 500's average ratio of 4.74
Corcept Therapeutics is part of the Health Care sector, which has an average P/E ratio of 26.07 and an average P/B of 3.53
CORT has reported YOY quarterly earnings growth of -8.9% and gross profit margins of 1.0%
The company has a free cash flow of $183.85 Million, which refers to the total sum of all its inflows and outflows of cash over the last quarter
Corcept Therapeutics Incorporated engages in discovery and development of medication for the treatment of severe endocrinologic, oncologic, metabolic, and neurologic disorders in the United States. It offers Korlym tablets medication for the treatment of hyperglycemia secondary to hypercortisolism in adult patients with endogenous cushing's syndrome; and who have type 2 diabetes mellitus or glucose intolerance and have failed surgery or are not candidates for surgery. The company is also developing relacorilant, which is in phase III clinical trial for the treatment of hypercortisolism; relacorilant combined with nab-paclitaxel which is in phase III clinical trial to treat platinum-resistant ovarian tumors; treatment for adrenal cancer and cortisol excess which is in phase 1b clinical trial; and for treatment for prostate cancer which is in phase II clinical trial. In addition, it develops dazucorilant, which is in phase II clinical trial for the treatment of amyotrophic lateral sclerosis; and miricorilant, which is in phase IIb trial for the treatment of metabolic dysfunction-associated steatohepatitis. The company was incorporated in 1998 and is headquartered in Redwood City, California.

The above analysis is intended for educational purposes only and was performed on the basis of publicly available data. It is not to be construed as a recommendation to buy or sell any security. Any buy, sell, or other recommendations mentioned in the article are direct quotations of consensus recommendations from the analysts covering the stock, and do not represent the opinions of Market Inference or its writers. Past performance, accounting data, and inferences about market position and corporate valuation are not reliable indicators of future price movements. Market Inference does not provide financial advice. Investors should conduct their own review and analysis of any company of interest before making an investment decision.